duloxetine hydrochloride has been researched along with Weight Gain in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alam, MY; Chen, Y; Jacobsen, PL; Mahableshwarkar, AR; Serenko, M | 1 |
| Alev, L; Ichibayashi, H; Ishida, M; Mizuno, H; Murakami, M; Nishioka, K; Ochiai, T; Osada, K | 1 |
| Duenas, H; Gaynor, P; McCarberg, B; Shoemaker, S; Zheng, W | 1 |
| Colman, SA; Harrison, GA; Hong, JP; Lee, MS; Lee, P; Liu, CY; Raskin, J; Ruschel, S; Shu, L; Wang, CY; Xu, X | 1 |
1 review(s) available for duloxetine hydrochloride and Weight Gain
| Article | Year |
|---|---|
Weight change with long-term duloxetine use in chronic painful conditions: an analysis of 16 clinical studies.
Topics: Aged; Analgesics; Arthralgia; Chronic Disease; Controlled Clinical Trials as Topic; Diabetic Neuropathies; Duloxetine Hydrochloride; Female; Fibromyalgia; Humans; Knee Joint; Low Back Pain; Male; Middle Aged; Osteoarthritis, Knee; Pain; Thiophenes; Weight Gain; Weight Loss | 2011 |
3 trial(s) available for duloxetine hydrochloride and Weight Gain
| Article | Year |
|---|---|
Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Depression; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Sexual Dysfunction, Physiological; Suicidal Ideation; Sulfides; Thiophenes; Treatment Outcome; Vortioxetine; Weight Gain; Young Adult | 2014 |
An open-label, long-term, phase III extension trial of duloxetine in Japanese patients with fibromyalgia.
Topics: Adult; Analgesics; Constipation; Duloxetine Hydrochloride; Female; Fibromyalgia; Humans; Male; Middle Aged; Nausea; Treatment Outcome; Weight Gain | 2017 |
Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Topics: Activities of Daily Living; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Blood Pressure; Brazil; China; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Heart Rate; Humans; Korea; Male; Middle Aged; Pain; Pain Measurement; Paroxetine; Psychiatric Status Rating Scales; Taiwan; Thiophenes; Weight Gain | 2007 |